seit 09/2020

Neurologie, Neurophysiologie und Schlafmedizin, Neurozentrum Luzern; sowie seit 2015 weiterhin Konsiliarius / Notfalldienst Neurologie, Belegarzt Klinik St.Anna Luzern

2019 – 2020

Schlafmedizin, Chefarzt Hofklinik für Wach- und Schlafmedizin, Luzern

2015 – 2018

Schlafmedizin, Chefarzt Klinik für Schlafmedizin, Luzern

1996 – 2015

Neurologie, Inselspital, Bern; Poliklinik inkl. Schlafmedizin; seit 2006 als OA EEG, Epileptologie und Schlaf¬medizin (2009 OA ENMG); Konsiliarius externe Spitäler und Neurointensivmedizin

1995

Neuroradiolgie, Inselspital, Bern / CT / MRI / Myeolographie

1994

Neurologie, Inselspital, Bern / klinische Neurologie / Schlafmedizin

1993 – 1994

Innere Medizin, Tiefenau-Spital, Bern

1989 – 1993

Neurologie, Inselspital, Bern / EEG / ENMG / Schlafmedizin

1988 – 1989

Neurochirurgie, Inselspital, Bern / Neurosonographie

1986 – 1987

Molekularbiologie, Ludwig Institute for Cancer Research

Facharzt- und Weiterbildungstitel, Zertifikate:

• Facharzt für Neurologie / Neurologie FMH
• Zerebrovaskuläre Krankheiten (neurovaskuläre Sonographie)
• Elektroneuromyographie (ENMG)
• Elektroenzephalographie (EEG)
• Schlafmedizin SGSSC (inkl. Polysomnographie, MSLT, MWT, Oxymetrie etc.)

2018

Prof: Titularprofessor für Neurologie, Universität Bern

2014

Prof: Assoziierter Professor für Neurologie, Universität Bern

2006

PD: Privatdozent für Neurologie, Universität Bern

1994

Dr. med: Doktortitel der Medizin, Universität Bern

1985

Staatsexamen Medizin, Universität Bern

1979

Maturität, Bern (Naturwissenschaftlicher Typus)

• FMH (Verband Schweizer Ärztinnen und Ärzte)
• SNG (Schweizerische Neurologische Gesellschaft)
• SGKN (Schweizerische Gesellschaft für Klinische Neurophysiologie)
• SGSSC (Schw. Gesellschaft für Schlafforschung, Schlafmedizin und Chronobiologie)
• Benesco (Bern Network for Epilepsy, Sleep and Consiousness) und andere

• Deutsch
• Englisch
• Französisch
• Italienisch

2009 – present

Chair of NeuroCentre Bellevue in Zurich. Clinician at NeuroCentre Enge Zurich, NeuroCentre Basel and NeuroCentre Aarau. Affiliated doctor at multiple Hirslanden Klinik locations (Klinik Hirslanden Zürich, Hirslanden Klinik Im Park Zürich, Hirslanden Klinik in Aarau, Andreasklinik in Cham)

2008 – 2009

Acting chair of Neurology and Neurosurgery Outpatient Clinic

2002 – 2008

Senior physician, Department of Neurology, University of Basel

2003 – 2005

Postdoctoral fellow in the Department of Neurology, Baylor College of Medicine and Methodist Neurological Institute, Houston, Texas, USA

1999 – 2002

Assistant physician, Department of Neurology, University of Basel

1998 – 1999

Assistant physician, Neurosurgery Clinic, Kantonsspital Aarau

1997 – 1998

Assistant physician, Neurology/Neurorehabilitation, Rehaklinik Rheinfelden

1995 – 1997

Assistant physician, Neurology/Internal Medicine, Swiss Paraplegic Center, Basel

1994 – 1995

Assistant physician, Internal Medicine, Kantonsspital Bruderholz

2010 – 2018

Member of the scientific advisory board of the Swiss Multiple Sclerosis Society

2008 – 2011

Vice President of the Swiss Muscle Society

2007

Postdoctoral tertiary teaching qualification, venia legendi, University of Basel

2003

SGKN certificate of competence in electroencephalography (EEG)

2003

SGKN certificate of competence electroneurography and electromyography (ENMG)

2002

FMH-certified neurology specialist

2001

Dissertation: “Predictive value of T2-lesion volume for the natural course of multiple sclerosis.” University of Basel, Prof. Dr. Ludwig Kappos

1987 – 1994

Studies in human medicine at Medical University of Gdansk, Poland and University of Basel, Switzerland Distinctions

Awards

• Recipient of the Sheila Essey Fellowship Award for ALS Research
• Fellow of the Swiss National Science Foundation
• Fellow of the Fonds zur Förderung des Akademischen Nachwuchses der Universität Basel
• Fellow of the Houston Endowment

• Swiss Neurological Society (SNG)
• Swiss Society for Clinical Neurophysiology (SGKN)
• European Neurological Society (ENS)
• American Academy of Neurology (AAN)
• Polish Neurological Society (PTN)
• Swiss Muscle Society (SGMK)
• Swiss Muscular Dystrophy Association (SGMK)
• Swiss Medical Association (FMH)

• German
• English
• Polish
• Russian

Prof. Adam Czaplinski is a regular speaker at neurological conferences in Europe and in the USA and the author of numerous publications.

Ocrelizumab in Switzerland – first experiences
Swiss Federation of Clinical Neurosocieties SFCNS, September 2017
Interlaken/Switzerland

TGA: an altitude sickness?
European Academy of Neurology, June 2017
Amsterdam/Netherlands

Real-life long-term effectiveness of fingolimod in a Swiss relapsing-remitting multiple sclerosis cohort
American Academy of Neurology, April 2017
Boston/USA

Final results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with RR-MS (SWISSASCENT)
ECTRIMS, September 2016
London/UK

Role of Family Planning in Women of Child-Bearing Age with Multiple Sclerosis (MS) in Switzerland: Results of the Women with MS (WWMS) Patient Survey
American Academy of Neurology April 2016
Vancouver/Canada

Alemtuzumab: real life experience in Switzerland
Swiss Federation of Clinical Neurosocieties SFCNS, November 2015
Bern/Switzerland

Fingolimod treatment induces changes in NK and T helper cell subpopulations and in T cell co-stimulation markers.
ECTRIMS, October 2015
Barcelona/Spain

Stem cells for Amyotrophic Lateral Sclerosis.
European Academy of Neurology Meeting, June 2015
Berlin/Germany

Adherence and compliance in MS therapy.
Polish Neurological Society, March 2015
Lodz/Poland

Alemtuzumab: restoring the immune system.
Swiss Neurological Society, October 2014
Interlaken/Switzerland

Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis (SWISSASCENT).
German Neurological Society, September 2014
Munich/Germany

Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis.
ECTRIMS/ACTRIMS Congress, September 2014
Boston/USA

Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis (SWISSASCENT).
European Neurological Society Congress, June 2014
Istanbul/Turkey

Prolonged-release fampridine in multiple sclerosis: improved ambulatory function by subject-specific changes of the walking pattern.
American Academy of Neurology Congress, Mai 2014
Philadelphia/USA

Swiss post marketing surveillance monitoring quality of life and treatment.
Journées de Neurologie de Langue Française, April 2014
Strasbourg/France

Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis (SWISSASCENT)
ECTRIMS Congress, October 2013
Copenhagen/Denmark

“Therapie der Multiplen Sklerose: vom Cortison zur differenzierten Immunomodulation.”
13th Swiss-Russian General Practitioners Conference, May 2013
St. Petersburg/Russia

“Tysabri in der Behandlung der Multiplen Sklerose”
MS State of The Art 2013, March 2013
Lodz/Poland

Novel electrochemiluminescence based immunoassay: neurofilament light chain in serum as a marker of axonal damage
William Harvey Day, Queen Mary University, October 2012
London/United Kingdom

A Swiss best practice experience in three different clinical settings of the 6 hour fingolimod observation procedure.
ECTRIMS Congress, October 2012
Lyon/France

Utilization of JC-Virus antibody testing in clinical practice.
ECTRIMS Congress, October 2012
Lyon/France

Tysabri: new data to efficacy and safety.
Central European Tysabri Advisory Board (CETAB) Meeting, October 2012
Vienna/Austria

Fingolimod in daily practice.
Swiss Neurological Society (SNG) Meeting, Mai 2012
Lugano/Switzerland

Update on current treatment strategies in MS
American Academy of Neurology (AAN) Meeting, participant, April 2012
New Orleans/USA

Tysabri: efficacy and safety update.
Central European Tysabri Advisory Board (CETAB) Meeting, January 2012
Bratislava/Slovakia

Personalized treatment strategies in Multiple Sclerosis.
ECTRIMS Congress, October 2011
Amsterdam/Netherlands

Treatment failure: what to do?
MS State of the Art, January 2011
Lucerne/Switzerland

MS therapy update.
ECTRIMS Congress, October 2010
Göteborg/Sweden

Current therapeutic strategies in MS.
European Neurological Society Congress (participant), June 2010
Berlin/Germany

Oral laquinimod for Multiple Sclerosis.
TEVA Symposium, Mai 2010
Jerusalem/Israel

The effect of IFNbeta 1b treatment on cognition in Multiple Sclerosis.
Advisory Board meeting, March 2010
Rome/Italy

Treatment failure, what to do?
Multiple Sclerosis State of the Art, Januar 2010
Luzern/Switzerland

Safety overview of fingolimod.
Fingolimod Advisory Board, December 2009
Berlin/Germany

New oral agents in the therapy of Multiple Sclerosis.
Cladribine Advisory Board, November 2009
Amsterdam/Netherlands

“Phasenadaptierte Therapie der Multiplen Sklerose.”
182nd conference of the Swiss Neurological Society, June 2009
Interlaken/Switzerland

Application of the Database Controls in Experimental Trials.
Annual Meeting of St.Lukes Hospital, April 2009
Tokyo/Japan

“ALS: Can We Predict the Course of Disease?”
19th congress of the Scientific Advisory Board of the DGM, March 2009
Darmstadt/Germany

Natalizumab in daily practice- risks and benefits.
11th State of the Art Symposium, January 2009
Berne/Switzerland

“Strategien zur Optimierung der immunomudulatorischen Therapie der MS.”
Zurich MS roundtable, October 2008
Zurich/Switzerland

“Moderne Therapie der Multiplen Sklerose”
Quadrimed Kongress, May 2008
Crans Montana/Switzerland

Reconsidering clinical outcomes: relapses, impairment, disability and beyond.
Symposium of the European Charcot Foundation, November 2007
Fiuggi/Italy

Length of prediagnostic period as a predictor of rate of disease progression and survival in ALS.
17th Meeting of the European Neurological Societ, June 2007
Rhodes/Greece

“Slower disease progression and prolonged survival in contemporary ALS patients: is the natural history of ALS changing?”
177th conference of the Swiss Neurological Society, October 2006
Interlaken/Switzerland

Amyotrophic Lateral Sclerosis: Can We Predict the Course of Disease?
Kongress der Polnischen Neurologischen Gesellschaft, September 2006
Krakow/Poland

Predictability of disease progression in amyotrophic lateral sclerosis.
XVIth Meeting of the European Neurological Society, Mai 2006
Lausanne/Switzerland

Slower disease progression and prolonged survival in contemporary ALS patients: is the natural history of ALS changing?
58th Annual Meeting of American Academy of Neurology, April 2006
San Diego/USA

Predictability of disease progression in amyotrophic lateral sclerosis.
16th International Symposium on ALS/MND, December 2005
Dublin/Ireland

Amyotrophic lateral sclerosis: early predictors of prolonged survival.
World Congress of Neurology, November 2005
Sydney/Australia

Application of the Database Controls in Experimental Trials for Amyotrophic Lateral Sclerosis.
57th Annual Meeting of American Academy of Neurology, April 2005
Miami/USA

Flail arm syndrome: a clinical variant of amyotrophic lateral sclerosis.
XIIIth Meeting of the European Neurological Society, June 2003
Istanbul/Turkey

Pathological crying as the initial presenting symptom in amyotrophic lateral sclerosis.
XIIIth Meeting of the European Neurological Society, June 2003
Istanbul/Turkey

Symptomatic care in ALS
Basler ALS Symposium, March 2003
Basel/Switzerland

Predictive value of T2-lesion volume for the natural course of multiple sclerosis.
Meeting of the Polish Neurological Society, September 200
Poznan/Poland

Rapid progressive, sensory-motor demyelinating neuropathy.
Xth International Neuromuscular Congress, July 2002
Vancouver/Canada

Ice pack test for myasthenia gravis: a simple, noninvasive and safe diagnostic method.
Xth International Neuromuscular Congress, July 2002
Vancouver/Canada

The natural course of multiple sclerosis: predictive value of lesion volume in T2-weighted brain MRI.
XIIth Meeting of the European Neurological Society, June 2002
Berlin/Germany

Necrotising  vasculitis and isotretinoin.
XIIth Meeting of the European Neurological Society, June 2002
Berlin/Germany

Scientific publications in PubMed database.